Anti-PML+RARA Rabbit Polyclonal Antibody for IF/ICC and ELISA - P29590 / P10276

Core Product Specifications and Parameters

Biological Background: PML+RARA Function and Localization

• The PML protein (Promyelocytic leukemia protein, TRIM19) is the scaffold component of PML nuclear bodies, functioning as a RING-type E3 SUMO ligase and participating in tumor suppression, transcriptional regulation, apoptosis, senescence, and antiviral defense. Related references: PMID:11500381, PMID:11575918, PMID:18391071, PMID:20972456, PMID:28250117
• In acute promyelocytic leukemia (APL), the t(15;17) chromosomal translocation creates the PML-RARA fusion oncoprotein, disrupting normal PML nuclear body formation and retinoic acid signaling.
• PML exhibits potent antiviral activity against a broad range of DNA and RNA viruses, often by sequestering viral components within PML nuclear bodies; isoforms PML-4 and PML-6 exhibit high SUMO ligase activity. Related references: PMID:20972456, PMID:28250117
• PML localizes primarily to the nucleus (nucleoplasm, PML bodies, nucleolus), but cytoplasmic isoforms also exist and can associate with the endoplasmic reticulum and early endosome membranes.
• The protein undergoes key post-translational modifications including SUMOylation, phosphorylation, and acetylation, which regulate its subcellular dynamics and interactions.
• PML is considered a tumor suppressor and proto-oncogene, depending on isoform context, and is involved in DNA damage response, telomerase regulation, and circadian rhythms.

Experimental Guidance and Technical Tips

• The immunogen spans residues 500-600 of PML and 1-100 of RARA, suggesting specificity toward the fusion junction; validation of reactivity with wild-type PML or RARA individually may be warranted.
• For IF/ICC, consider using APL-derived cell lines (e.g., NB4) that express the PML-RARA fusion; a microspeckled nuclear pattern indicates disruption of normal PML bodies.
• In ELISA, titration of the antibody against recombinant PML-RARA or peptide antigens is recommended to establish optimal working concentrations.
• Cross-reactivity with rat samples is reported, but sequence alignment of the immunogen region in rat PML and RARA is advisable to confirm epitope conservation.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio provides diagnostic manufacturers, laboratories, and research institutes with a seamless supply chain for IVD raw materials, including validated antibody pairs, optimized monoclonal/polyclonal antibodies, and bulk ancillary reagents. This polyclonal antibody targeting the PML-RARA fusion protein supports APL leukemia research and immunoassay development, with CamelBio offering end-to-end sourcing services from target identification to clinical translation. We also specialize in the custom procurement of rare-target raw materials, ensuring your projects stay on track from concept to clinic.